{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:23:19Z","timestamp":1767651799589},"reference-count":0,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":15253,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1974,4]]},"abstract":"<jats:p>The usefulness of urinary glucaric acid determinations to measure enzyme induction by drugs was investigated by correlating its excretion rate with the daily drug regimen of 100 hospitalized patients. The urinary excretion of glucaric acid was higher in patients than in normal controls. Patients treated with enzyme inducers excreted more glucaric acid than patients not getting them, as well as more than normal controls. In patients on multiple\u2010drug therapy, the effect of small doses of known enzyme inducers was masked, but even here relatively high doses of potent inducers significantly increased glucaric acid excretion. The results also suggest that urinary excretion of glucaric acid may have value as an indicator of the use of certain drugs by patients when such information is not revealed by the history.<\/jats:p>","DOI":"10.1002\/cpt1974154417","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:28:07Z","timestamp":1451957287000},"page":"417-423","source":"Crossref","is-referenced-by-count":27,"title":["Glucaric acid as an indicator of use of enzyme\u2010inducing drugs"],"prefix":"10.1111","volume":"15","author":[{"given":"Eero A.","family":"Sotaniemi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fedor","family":"Medzihradsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudmundur","family":"Eliasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1974154417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1974154417","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt1974154417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:29:33Z","timestamp":1699363773000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt1974154417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1974,4]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1974,4]]}},"alternative-id":["10.1002\/cpt1974154417"],"URL":"https:\/\/doi.org\/10.1002\/cpt1974154417","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1974,4]]}}}